Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke

Table 4 Comparison of serum antibody levels of HDs versus those of patients with chronic kidney disease (CKD)

Sample information		HD	Type-1 CKD	Type-2 CKD	Type-3 CKD
Total sample number		82	145	32	123
Male/female		44/38	106/39	21/11	70/53
Age (average ± SD)		44.1 ± 11.2	66.0 ± 10.4	76.0 ± 9.8	62.0 ± 11.7
Alpha analysis (antibody level)		DIDO1-Ab	FOXJ2-Ab	CPSF2-Ab
HD	Average	3166	1300	914
	SD	1423	517	298
	Cutoff value	6012	2334	1509
	Positive no.	6	3	3
	Positive rate (%)	7.3%	3.7%	3.7%
Type 1-CKD	Average	6805	2141	939
	SD	4675	1330	382
	Positive no.	63	41	7
	Positive rate (%)	43.4%	28.3%	4.8%
	P (vs HD)	< 0.0001	< 0.0001	0.579
Type 2-CKD	Average	6693	2245	1020
	SD	3347	930	281
	Positive no.	12	11	2
	Positive rate (%)	37.5%	34.4%	6.3%
	P (vs HD)	< 0.0001	< 0.0001	0.081
Type 3-CKD	Average	5264	1770	936
	SD	2161	829	421
	Positive no.	33	17	10
	Positive rate (%)	26.8%	13.8%	8.1%
	P (vs HD)	< 0.0001	< 0.0001	0.656

CKD types 1, 2, and 3 correspond to diabetic kidney disease, nephrosclerosis, and glomerulonephritis, respectively. The upper panel indicates the numbers of all samples and samples from males and females as well as age (average ± SD). The lower panel summarizes the serum antibody levels examined by AlphaLISA using purified DIDO1-GST protein and synthetic bCPSF2 and bFOXJ2 peptides as antigens as described in the legend of Table 2. Box-whisker plots of the same results are shown in Fig. 4a, e, and i. P values lower than 0.05 and positive rates higher than 10% are marked in bold

ISSN: 1741-7015